MERCK & CO., INC. (MRK)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business